Journal of Clinical Lipidology
Volume 4, Issue 5 , Pages 420-426 , September 2010

Complete Apo AI Deficiency in an Iraqi Mandaean Family: Case studies and review of the literature

  • Ahmad Al-Sarraf, MD

      Affiliations

    • Healthy Heart Program Prevention Clinic, St. Paul's Hospital, 1081 Burrard Street, Vancouver, British Columbia, Canada, BC V6Z 1Y6
    • Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
    • Both authors contributed as first author.
    • ,
  • Khalid Al-Ghofaili, MD, FRCP(C)

      Affiliations

    • Healthy Heart Program Prevention Clinic, St. Paul's Hospital, 1081 Burrard Street, Vancouver, British Columbia, Canada, BC V6Z 1Y6
    • Both authors contributed as first author.
    • ,
  • David R. Sullivan, MBBS, FRACP, FRCPA

      Affiliations

    • Department of Clinical Biochemistry, Royal Prince Alfred Hospital, New South Wales, Australia
    • ,
  • Kishor M. Wasan, RPh, PhD

      Affiliations

    • Faculty of Pharmaceutical Sciences, UBC, Vancouver, BC, Canada
    • ,
  • Robert Hegele, MD, FRCP(C), FACP

      Affiliations

    • Roberts Research Institute, London, Ontario, Canada
    • ,
  • Jiri Frohlich, MD, FRCP(C)

      Affiliations

    • Healthy Heart Program Prevention Clinic, St. Paul's Hospital, 1081 Burrard Street, Vancouver, British Columbia, Canada, BC V6Z 1Y6
    • Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
    • Corresponding Author InformationCorresponding author.

Received 22 March 2010 ,Accepted 17 May 2010.

References 

  1. Hovingh GK, de Groot E, van der Steeg W, et al. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol. 2005;16:139–415
  2. Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB. Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis. 1982;2:16–26
  3. Norum RA, Lakier JB, Goldstein S, et al. Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease. N Engl J Med. 1982;306:1513–1519
  4. Funke H, von Eckardstein A, Pritchard PH, Karas M, Albers JJ, Assmann G. A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin: cholesterol-acyltransferase deficiency, and corneal opacities. J Clin Invest. 1991;87:371–376
  5. Matsunaga T, Hiasa Y, Yanagi H, et al. Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene. Proc Natl Acad Sci U S A. 1991;88:2793–2797
  6. Lackner KJ, Dieplinger H, Nowicka G, Schmitz G. High density lipoprotein deficiency with xanthomas. A defect in reverse cholesterol transport caused by a point mutation in the apolipoprotein A-I gene. J Clin Invest. 1993;92:2262–2273
  7. Ng DS, Leiter LA, Vezina C, Connelly PW, Hegele RA. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest. 1994;93:223–229
  8. Römling R, von Eckardstein A, Funke H, Motti C, Fragiacomo GC, Noseda G, et al. A nonsense mutation in the apolipoprotein A-I gene is associated with high-density lipoprotein deficiency and periorbital xanthelasmas. Arterioscler Thromb. 1994;14:1915–1922
  9. Takata K, Saku K, Ohta T, et al. A new case of apoA-I deficiency showing codon 8 nonsense mutation of the apoA-I gene without evidence of coronary heart disease. Arterioscler Thromb Vasc Biol. 1995;15:1866–1874
  10. Miccoli R, Bertolotto A, Navalesi R, et al. Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease. Circulation. 1996;94:1622–1628
  11. Moriyama K, Sasaki J, Takada Y, et al. A cysteine-containing truncated apo A-I variant associated with HDL deficiency. Arterioscler Thromb Vasc Biol. 1996;16:1416–1423
  12. Huang W, Sasaki J, Matsunaga A, et al. A novel homozygous missense mutation in the apo A-I gene with apo A-I deficiency. Arterioscler Thromb Vasc Biol. 1998;18:389–396
  13. Matsunaga A, Sasaki J, Han H, et al. Compound heterozygosity for an apolipoprotein A1 gene promoter mutation and a structural nonsense mutation with apolipoprotein A1 deficiency. Arterioscler Thromb Vasc Biol. 1999;19:348–355
  14. Yokota H, Hashimoto Y, Okubo S, et al. Apolipoprotein A-I deficiency with accumulated risk for CHD but no symptoms of CHD. Atherosclerosis. 2002;162:399–407
  15. Pisciotta L, Miccoli R, Cantafora A, et al. Recurrent mutations of the apolipoprotein A-I gene in three kindreds with severe HDL deficiency. Atherosclerosis. 2003;167:335–345
  16. Ikewaki K, Matsunaga A, Han H, et al. A novel two nucleotide deletion in the apolipoprotein A-I gene, apoA-I Shinbashi, associated with high density lipoprotein deficiency, corneal opacities, planar xanthomas, and premature coronary artery disease. Atherosclerosis. 2004;172:39–45
  17. Santos RD, Schaefer EJ, Asztalos BF, et al. Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. J Lipid Res. 2008;49:349–357
  18. Moore RE, Navab M, Millar JS, et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res. 2005;97:763–771
  19. Tory R, Sachs-Barrable K, Hill JS, Wasan KM. Cyclosporine A and Rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma. Int J Pharmacol. 2008;358:219–223
  20. Kanna S, Kuniko O-N, Takeshi H, et al. Human cholesteryl ester transfer protein measured by enzyme-linked immunosorbent assay with two monoclonal antibodies against rabbit cholesteryl ester transfer protein: plasma cholesteryl ester transfer protein and lipoproteins among Japanese hypercholesterolemic patients. Clin Chem. 1998;44:1466–1473
  21. Dobiásová M, Frohlich J. Measurement of fractional esterification rate of cholesterol in plasma depleted of apoprotein B containing lipoprotein: methods and normal values. Physiol Res. 1996;45:65–73
  22. Bøyum A. Separation of lymphocytes, granulocytes, and monocytes from human blood using iodinated density gradient media. Methods Enzymol. 1984;108:88–102
  23. Becq F, Hamon Y, Bajetto A, Gola M, Verrier B, Chimini G. ABC1, an ATP binding cassette transporter required for phagocytosis of apoptotic cells, generates a regulated anion flux after expression in Xenopus laevis oocytes. J Biol Chem. 1997;272:2695–2699
  24. Langmann T, Klucken J, Reil M, et al. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Commun. 1999;257:29–33
  25. Garner B, Baoutina A, Dean RT, Jessup W. Regulation of serum-induced lipid accumulation in human monocyte-derived macrophages by interferon-gamma. Correlations with apolipoprotein E production, lipoprotein lipase activity and LDL receptor-related protein expression. Atherosclerosis. 1997;128:47–58
  26. Chan S, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol. 2003;42:1037–1043
  27. Fialová L, Malbohan I, Kalousová M, et al. Oxidative stress and inflammation in pregnancy. Scand J Clin Lab Invest. 2006;66:121–127
  28. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2001;21:13–27
  29. Calabresi L, Sirtori CR, Paoletti R, Franceschini G. Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases. Curr Atheroscler Rep. 2006;8:163–167
  30. Hughes SD, Verstuyft J, Rubin EM. HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis. Arterioscler Thromb Vasc Biol. 1997;17:1725–1729
  31. Voyiaziakis E, Goldberg IJ, Plump AS, Rubin EM, Breslow JL, Huang LS. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. J Lipid Res. 1998;39:313–321
  32. Barter P, Gotto AM, LaRosa JC, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–1310
  33. Hovingh GK, Brownlie A, Bisoendial RJ, et al. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol. 2004;44:1429–1435

PII: S1933-2874(10)00223-0

doi: 10.1016/j.jacl.2010.05.001

Journal of Clinical Lipidology
Volume 4, Issue 5 , Pages 420-426 , September 2010

Article Tools

* Image Usage & Resolution